US Drug Pricing Reforms Testing Limits Of Executive Action
Executive Summary
Congressional inaction on drug pricing legislation has meant the Trump Administration is pursuing a menu of regulatory approaches. For the most part, that means slower and incremental change.
You may also be interested in...
Part D Premiums ‘Won’t Go Up’ With HHS Rebate Proposal, Azar Maintains
US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.
No, It's Not Just Out-Of-Pocket Costs That Are A Problem, John Arnold Tells Pharma
The billionaire philanthropist and industry agitator took the stage at the Forbes Healthcare Summit to discuss why his foundation is focused on fixing drug pricing and supporting organizations like ICER and Patients for Affordable Drugs.
On Drug Price Increases, Pfizer's Read Expects ‘Business As Normal’ In 2019
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.